Table 1.
GA101 | LFB-R603 | BLX-301 | |
---|---|---|---|
Company | Roche [Glycart] | LFB Biotechnologies [GTC Biotherapeutics] | Biolex |
Format | Humanized | Chimæric | Humanized |
Type of anti-CD20 | Type II | Type I | NA |
Glyco-engineering | Low fucose | Low fucose | No fucose / G0 |
CDC* | ↘ | = | ↘ |
ADCC** | ↗ | ↗ | ↗ |
PCD° | ↗ | = | NA°° |
Phase Development | Phase II | Phase I/II | Pre-clinical |
Indication | NHL / CLL+ | CLL | NHL |
Reference | [51] | [34] | NA |
* CDC: complement-dependent cytotoxicity, ** ADCC: antibody-dependent cell cytotoxicity; ° PCD: programmed cell death induction, °° NA: not available; + CLL: chronic lymphocytic leukemia.